Business, energy, technology, markets and global industry news from Business News Today

National Medical Products Administration

PharmaDeviceNews National Medical Products Administration
Representative image: Laboratory researchers assess an oral blood disorder therapy as Nuvectis Pharma’s ciprocopan secures China approval for treatment-naive paroxysmal nocturnal hemoglobinuria.
Pharma & Biotech

Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option

Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.

Read More
Zai Lab prepares to report second-quarter 2026 results as investors assess revenue recovery, new China product launches and progress across its oncology and neuroscience pipeline. Representative image.
Pharma & Biotech

Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work

Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.

Read More
Kelun-Biotech’s sacituzumab tirumotecan plus pembrolizumab met the Phase III PFS endpoint in first-line PD-L1-negative non-squamous NSCLC. Representative image.
Pharma & Biotech

Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests

Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.

Read More
Lynk Pharmaceuticals completes patient enrollment in the Phase III zemprocitinib trial evaluating the oral JAK1 inhibitor for active ankylosing spondylitis. Representative image.
Pharma & Biotech

What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline

Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.

Read More
Leads Biolabs secures China priority review for opamtistomig in advanced extrapulmonary neuroendocrine carcinoma, advancing its bispecific cancer immunotherapy toward approval. Representative image.
Pharma & Biotech

Leads Biolabs wins China priority review for opamtistomig in advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. has secured priority review in China for the biologics licence application covering opamtistomig as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma after at least two previous systemic treatment lines. The July 10, 2026 decision moves the Hong Kong-listed biotechnology company, traded under stock code 9887, closer to a possible first

Read More
Representative image: Cancer research team reviews tumor data as Harbour BioMed’s HBM7004 advances toward clinical testing for advanced solid tumors.
Pharma & Biotech

Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets

Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Pharma & Biotech

Lupin just cracked China with a flu drug. Why investors may want to look closer

Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.

Read More
Representative image: Chance Pharmaceuticals’ CXG87 asthma inhalation therapy filing in China highlights how improved dry powder inhaler design could reshape respiratory drug delivery and asthma control.
Pharma & Biotech

Can Chance Pharma’s asthma inhaler challenge Symbicort’s grip on China’s respiratory market?

Asthma drugs are familiar. Delivery remains the problem. CXG87 could test whether better inhaler engineering changes China’s asthma market.

Read More
Representative image: Mabwell’s 9MW5211 FDA clearance highlights growing clinical interest in first-in-class antibody therapies for inflammatory bowel disease, as biotech developers target pathogenic immune cells to reshape autoimmune disease treatment.
Pharma & Biotech

Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?

Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.

Read More